Jazz Pharmaceuticals - JAZZ Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $192.75
Forecasted Upside: 76.85%
Number of Analysts: 13
Breakdown:
0 Sell Ratings
2 Hold Ratings
11 Buy Ratings
0 Strong Buy Ratings

^$108.99 As of 05/17/2024 01:00 AM ET

▼ -1.5 (-1.36%)

1 month | 3 months | 12 months

Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

^$192.75

▲ +76.85% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $192.75, with a high forecast of $230.00 and a low forecast of $131.00. The average price target represents a 76.85% upside from the last price of $108.99.

Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in Jazz Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/24/2022

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/22/2023

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/23/2023

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/21/2023

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/19/2023

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/17/2024

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/17/2024

0 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/17/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/3/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$200.00	Low
5/3/2024	Barclays	Lower Target	Overweight ➝ Overweight	$230.00 ➝ $200.00	Low
5/2/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$222.00	Low
4/10/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$180.00	Low
3/22/2024	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$170.00 ➝ $190.00	Low
3/22/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$180.00	Low
3/20/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$200.00	Low
3/20/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$220.00	Low
3/20/2024	Piper Sandler	Boost Target	Overweight ➝ Overweight	$171.00 ➝ $188.00	Low
3/15/2024	Stifel Nicolaus	Boost Target	Buy ➝ Buy	$225.00 ➝ $230.00	Low
3/14/2024	HC Wainwright	Lower Target	Buy ➝ Buy	$204.00 ➝ $200.00	Low
3/1/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$135.00 ➝ $131.00	Low
3/1/2024	Barclays	Lower Target	Overweight ➝ Overweight	$235.00 ➝ $230.00	Low
2/29/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$180.00	Low
2/29/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$195.00	Low
2/29/2024	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$180.00 ➝ $170.00	Low
2/29/2024	Needham & Company LLC	Lower Target	Buy ➝ Buy	$225.00 ➝ $220.00	Low
1/29/2024	Barclays	Lower Target	Overweight ➝ Overweight	$240.00 ➝ $235.00	Low
1/3/2024	Robert W. Baird	Initiated Coverage	Outperform	$160.00	Low
12/4/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$200.00	Low
11/29/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$225.00	Low
11/27/2023	UBS Group	Downgrade	Buy ➝ Neutral	$170.00 ➝ $135.00	Low
11/9/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$200.00 ➝ $191.00	Low
11/9/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$226.00 ➝ $225.00	Low
9/28/2023	Raymond James	Initiated Coverage	Market Perform		Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$180.00	Low
8/14/2023	Cantor Fitzgerald	Lower Target	Overweight ➝ Overweight	$210.00 ➝ $180.00	Low
8/11/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$204.00	Low
8/10/2023	Bank of America	Boost Target	Buy ➝ Buy	$204.00 ➝ $217.00	Low
8/10/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$203.00 ➝ $201.00	Low
8/7/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$226.00	Low
7/10/2023	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
5/11/2023	Royal Bank of Canada	Lower Target		$207.00 ➝ $202.00	Low
5/11/2023	Needham & Company LLC	Boost Target		$205.00 ➝ $212.00	Low
3/6/2023	HC Wainwright	Reiterated Rating	Buy	$204.00	Low
3/3/2023	The Goldman Sachs Group	Boost Target	Buy	$190.00 ➝ $212.00	Low
3/2/2023	Needham & Company LLC	Lower Target	Buy	$210.00 ➝ $205.00	Low
12/8/2022	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$192.00 ➝ $190.00	Low
11/10/2022	The Goldman Sachs Group	Boost Target	Neutral	$170.00 ➝ $192.00	Low
11/10/2022	Royal Bank of Canada	Boost Target	Outperform	$206.00 ➝ $207.00	Low
11/10/2022	Needham & Company LLC	Lower Target	Buy	$210.00 ➝ $208.00	Low
9/29/2022	The Goldman Sachs Group	Boost Target	Neutral	$148.00 ➝ $170.00	Low
9/21/2022	The Goldman Sachs Group	Lower Target	Neutral	$192.00 ➝ $148.00	Low
8/5/2022	HC Wainwright	Lower Target		$210.00 ➝ $204.00	Low
8/4/2022	BMO Capital Markets	Boost Target	Outperform	$185.00 ➝ $188.00	Low
8/4/2022	SVB Leerink	Boost Target	Outperform	$200.00 ➝ $210.00	Low
8/4/2022	UBS Group	Lower Target	Buy	$194.00 ➝ $191.00	Low
8/4/2022	Morgan Stanley	Boost Target	Equal Weight	$174.00 ➝ $187.00	N/A
6/13/2022	UBS Group	Initiated Coverage	Buy	$194.00	Medium
5/5/2022	Cowen	Boost Target		$200.00 ➝ $225.00	Low
5/5/2022	Cowen	Boost Target		$200.00 ➝ $225.00	Low
5/5/2022	Piper Sandler	Lower Target		$197.00 ➝ $193.00	Low
4/6/2022	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$202.00 ➝ $196.00	High
3/3/2022	HC Wainwright	Boost Target	Buy	$210.00 ➝ $215.00	Low
3/2/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
3/2/2022	Piper Sandler	Lower Target	Overweight	$209.00 ➝ $197.00	High
3/2/2022	Royal Bank of Canada	Lower Target	Outperform	$216.00 ➝ $214.00	High
3/2/2022	BMO Capital Markets	Lower Target		$202.00 ➝ $187.00	High
2/7/2022	Needham & Company LLC	Reiterated Rating	Buy	$215.00	Low
1/20/2022	Truist Financial	Boost Target		$180.00 ➝ $200.00	Low
12/20/2021	SVB Leerink	Lower Target	Outperform	$230.00 ➝ $200.00	Low
12/17/2021	Needham & Company LLC	Lower Target	Buy	$220.00 ➝ $215.00	Medium
11/18/2021	The Goldman Sachs Group	Initiated Coverage	Buy		High
10/8/2021	Morgan Stanley	Lower Target	Equal Weight	$176.00 ➝ $174.00	Low
10/5/2021	Citigroup	Initiated Coverage	Buy	$200.00	Medium
9/22/2021	Needham & Company LLC	Initiated Coverage	Buy	$220.00	High
8/16/2021	HC Wainwright	Lower Target	Buy	$220.00 ➝ $210.00	Low
7/23/2021	Royal Bank of Canada	Boost Target	Outperform	$190.00 ➝ $216.00	Low
7/22/2021	SVB Leerink	Reiterated Rating	Buy		Low
7/6/2021	Jefferies Financial Group	Initiated Coverage	Buy	$220.00	Low
6/22/2021	Barclays	Boost Target	Overweight	$235.00 ➝ $250.00	Low
6/21/2021	HC Wainwright	Boost Target	Buy	$212.00 ➝ $220.00	Low
6/18/2021	SVB Leerink	Boost Target	Outperform	$210.00 ➝ $230.00	Low
5/24/2021	Piper Sandler	Reiterated Rating	Buy	$214.00	Low
5/19/2021	JPMorgan Chase & Co.	Initiated Coverage	Overweight		Low
5/17/2021	HC Wainwright	Boost Target	Buy	$207.00 ➝ $212.00	Medium
5/9/2021	SVB Leerink	Reiterated Rating	Buy		Low
5/7/2021	Jefferies Financial Group	Reiterated Rating	Buy		Low
4/21/2021	Cantor Fitzgerald	Boost Target	Overweight	$185.00 ➝ $198.00	Medium
4/14/2021	Stifel Nicolaus	Boost Target	Buy	$195.00 ➝ $202.00	High
4/1/2021	Morgan Stanley	Boost Target	Equal Weight	$162.00 ➝ $176.00	Low
3/15/2021	SVB Leerink	Reiterated Rating	Outperform		Medium
3/1/2021	UBS Group	Boost Target	Buy	$174.00 ➝ $228.00	Low
2/25/2021	SVB Leerink	Lower Target	Outperform	$213.00 ➝ $210.00	Medium
2/24/2021	Cowen	Boost Target	Outperform	$190.00 ➝ $200.00	High
2/24/2021	Jefferies Financial Group	Boost Target	Buy	$209.00 ➝ $214.00	High
2/24/2021	Piper Sandler	Boost Target	Overweight	$175.00 ➝ $205.00	High
2/5/2021	HC Wainwright	Boost Target	Buy	$195.00 ➝ $207.00	High
2/3/2021	Piper Sandler	Upgrade	Neutral ➝ Overweight	$150.00 ➝ $175.00	High
1/29/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$177.00 ➝ $162.00	High
12/15/2020	UBS Group	Initiated Coverage	Buy	$174.00	High
11/3/2020	Wells Fargo & Company	Boost Target	Overweight	$171.00 ➝ $184.00	High
11/3/2020	Royal Bank of Canada	Boost Target	Outperform	$170.00 ➝ $180.00	High
11/3/2020	Barclays	Boost Target	Overweight	$225.00 ➝ $233.00	High
11/3/2020	SVB Leerink	Boost Target	Outperform	$194.00 ➝ $202.00	High
11/3/2020	HC Wainwright	Boost Target	Buy	$185.00 ➝ $195.00	High
10/26/2020	Barclays	Boost Target	Overweight	$205.00 ➝ $225.00	Low
10/20/2020	Truist Financial	Boost Target		$157.00 ➝ $175.00	Medium
10/9/2020	Jefferies Financial Group	Boost Target	Buy	$151.00 ➝ $188.00	Low
10/9/2020	SVB Leerink	Boost Target	Outperform	$164.00 ➝ $182.00	Low
10/9/2020	HC Wainwright	Boost Target	Buy	$175.00 ➝ $185.00	Low
9/14/2020	Royal Bank of Canada	Boost Target		$160.00 ➝ $170.00	Low
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$175.00	Medium
9/14/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$128.00	Medium
8/13/2020	Wells Fargo & Company	Boost Target	Overweight	$150.00 ➝ $171.00	Low
8/6/2020	Barclays	Reiterated Rating	Buy		High
8/6/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$177.00	High
7/30/2020	Oppenheimer	Initiated Coverage	Outperform		High
7/28/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform		Low
7/23/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$145.00 ➝ $166.00	Medium
6/23/2020	Barclays	Boost Target	Overweight	$183.00 ➝ $195.00	Low
6/18/2020	Bank of America	Boost Target	Buy	$165.00 ➝ $167.00	Low
6/1/2020	SVB Leerink	Boost Target	Outperform	$160.00 ➝ $169.00	Low
5/6/2020	SunTrust Banks	Lower Target	Buy	$155.00 ➝ $153.00	Medium
5/6/2020	Oppenheimer	Reiterated Rating	Buy	$132.00	Medium
5/6/2020	SVB Leerink	Lower Target	Outperform	$169.00 ➝ $160.00	Medium
5/6/2020	BMO Capital Markets	Lower Target	Positive ➝ Outperform	$205.00 ➝ $193.00	High
5/6/2020	Piper Sandler	Lower Target	Neutral	$127.00 ➝ $113.00	High
4/30/2020	Wells Fargo & Company	Lower Target	Overweight	$189.00 ➝ $162.00	Low
4/30/2020	Oppenheimer	Lower Target	Outperform	$154.00 ➝ $141.00	Low
4/6/2020	Jefferies Financial Group	Initiated Coverage	Buy	$149.00	High
4/2/2020	Morgan Stanley	Lower Target	Equal Weight	$147.00 ➝ $109.00	Medium
3/30/2020	Royal Bank of Canada	Lower Target		$164.00 ➝ $174.00	Medium
3/23/2020	Bank of America	Lower Target	Buy	$178.00 ➝ $163.00	High
3/12/2020	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$175.00 ➝ $166.00	High
2/27/2020	SunTrust Banks	Lower Target	Buy	$171.00 ➝ $166.00	High
2/26/2020	Oppenheimer	Lower Target		$183.00 ➝ $154.00	High
2/26/2020	Piper Sandler	Lower Target		$142.00 ➝ $129.00	High
2/26/2020	BMO Capital Markets	Lower Target	Outperform	$208.00 ➝ $205.00	High
2/26/2020	Royal Bank of Canada	Reiterated Rating	Outperform	$164.00	High
2/26/2020	Cowen	Lower Target	Outperform	$200.00 ➝ $165.00	High
2/26/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$173.00 ➝ $183.00	High
1/31/2020	SunTrust Banks	Reiterated Rating	Buy	$166.00 ➝ $171.00	Low
1/22/2020	Wells Fargo & Company	Boost Target	Overweight	$186.00 ➝ $189.00	Low
1/8/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$153.00	Medium
12/3/2019	Wells Fargo & Company	Boost Target	Outperform	$168.00 ➝ $186.00	High
12/2/2019	Barclays	Boost Target	Overweight	$182.00 ➝ $200.00	Low
11/11/2019	HC Wainwright	Reiterated Rating	Hold	$147.00	Medium
11/11/2019	Evercore ISI	Reiterated Rating	Buy		Medium
11/7/2019	Barclays	Reiterated Rating	Buy	$182.00	Medium
10/14/2019	Sanford C. Bernstein	Reiterated Rating	Market Perform	$150.00	Low
9/26/2019	Oppenheimer	Set Target	Buy	$176.00	Low
8/21/2019	Piper Sandler Companies	Downgrade	Overweight ➝ Neutral	$205.00 ➝ $142.00	High
8/14/2019	Wells Fargo & Company	Reiterated Rating	Buy		Low
8/12/2019	Evercore ISI	Reiterated Rating	Buy		Medium
8/8/2019	HC Wainwright	Reiterated Rating	Hold	$147.00	Low
8/7/2019	Barclays	Boost Target	Overweight	$164.00 ➝ $180.00	High
7/8/2019	Oppenheimer	Set Target	Buy	$176.00	Low
7/3/2019	Royal Bank of Canada	Set Target	Buy	$184.00	Low
7/3/2019	Barclays	Set Target	Buy	$164.00	Low
7/3/2019	BMO Capital Markets	Set Target	Buy	$208.00	Low
7/3/2019	Mizuho	Set Target	Hold	$148.00	Low
6/17/2019	Wells Fargo & Company	Reiterated Rating	Buy		Low
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$164.00	Low
5/28/2019	Piper Sandler Companies	Set Target	Buy	$202.00	Low

(Data available from 5/18/2019 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

13 very positive mentions
12 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

10/21/2023

4 very positive mentions
17 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/20/2023

8 very positive mentions
8 positive mentions
1 negative mentions
4 very negative mentions

Mentions as of

12/20/2023

5 very positive mentions
8 positive mentions
7 negative mentions
2 very negative mentions

Mentions as of

1/19/2024

21 very positive mentions
14 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

2/18/2024

26 very positive mentions
27 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

3/19/2024

20 very positive mentions
10 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

4/18/2024

24 very positive mentions
17 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

5/18/2024

Current Sentiment

Recent Stories by Sentiment

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $108.99

$108.21

$110.13

50 Day Range

MA: $114.22

$107.10

$125.00

52 Week Range

Now: $108.99

$103.01

$146.70

Volume

574,031 shs

Average Volume

621,292 shs

Market Capitalization

$6.87 billion

P/E Ratio

22.47

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?: The following Wall Street research analysts have issued stock ratings on Jazz Pharmaceuticals in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for JAZZ.
What is the current price target for Jazz Pharmaceuticals?: 12 Wall Street analysts have set twelve-month price targets for Jazz Pharmaceuticals in the last year. Their average twelve-month price target is $192.75, suggesting a possible upside of 76.9%. Stifel Nicolaus has the highest price target set, predicting JAZZ will reach $230.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $131.00 for Jazz Pharmaceuticals in the next year.
View the latest price targets for JAZZ.
What is the current consensus analyst rating for Jazz Pharmaceuticals?: Jazz Pharmaceuticals currently has 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JAZZ.
What other companies compete with Jazz Pharmaceuticals?: Other companies that are similar to Jazz Pharmaceuticals include Perrigo, Mirati Therapeutics, Corcept Therapeutics, Intra-Cellular Therapies and Ascendis Pharma A/S. Learn More about companies similar to Jazz Pharmaceuticals.
How do I contact Jazz Pharmaceuticals' investor relations team?: Jazz Pharmaceuticals' physical mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company's listed phone number is (531) 634-7800 and its investor relations email address is [email protected]. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. Learn More about contacing Jazz Pharmaceuticals investor relations.

Jazz Pharmaceuticals - JAZZ Stock Price Target and Predictions

Analyst Price Target for JAZZ

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.76 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?

What is the current price target for Jazz Pharmaceuticals?

What is the current consensus analyst rating for Jazz Pharmaceuticals?

What other companies compete with Jazz Pharmaceuticals?

How do I contact Jazz Pharmaceuticals' investor relations team?